NEVRO CORP (NVRO) Stock Price, Forecast & Analysis
USA - NYSE:NVRO - US64157F1030 - Common Stock
NVRO Key Statistics, Chart & Performance
The current stock price of NVRO is 5.84 USD. In the past month the price increased by 0.86%. In the past year, price decreased by -56.06%.
NVRO Latest News, Press Relases and Analysis
NVRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.9 | 224.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.68 | 202.72B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.59 | 155.55B | ||
| SYK | STRYKER CORP | 28.35 | 142.76B | ||
| IDXX | IDEXX LABORATORIES INC | 55.63 | 56.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.51 | 50.56B | ||
| RMD | RESMED INC | 25.47 | 36.79B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.12 | 33.77B | ||
| PODD | INSULET CORP | 72.79 | 23.42B | ||
| DXCM | DEXCOM INC | 32.11 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.2 | 17.94B |
Related stock screener links
About NVRO
Company Profile
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Company Info
NEVRO CORP
1800 Bridge Parkway
Redwood City CALIFORNIA 94065 US
CEO: D. Keith Grossman
Employees: 1099
Phone: 16502510005
NEVRO CORP / NVRO FAQ
What does NVRO do?
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Can you provide the latest stock price for NEVRO CORP?
The current stock price of NVRO is 5.84 USD.
Does NEVRO CORP pay dividends?
NVRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVRO stock?
NVRO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for NVRO stock?
NEVRO CORP (NVRO) will report earnings on 2025-05-05, after the market close.
Can you provide the ownership details for NVRO stock?
You can find the ownership structure of NEVRO CORP (NVRO) on the Ownership tab.
NVRO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NVRO. When comparing the yearly performance of all stocks, NVRO is one of the better performing stocks in the market, outperforming 72.33% of all stocks.
NVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVRO. NVRO may be in some trouble as it scores bad on both profitability and health.
NVRO Financial Highlights
Over the last trailing twelve months NVRO reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS increased by 25.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -49.11% | ||
| Debt/Equity | 0.98 |
NVRO Forecast & Estimates
19 analysts have analysed NVRO and the average price target is 8.87 USD. This implies a price increase of 51.87% is expected in the next year compared to the current price of 5.84.
For the next year, analysts expect an EPS growth of -29.92% and a revenue growth 0.32% for NVRO